NCT02389231View on ClinicalTrials.gov

Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

November 16, 2018

Study Completion Date

November 16, 2018

Conditions
Autoimmune Hemolytic Anemia
Interventions
DRUG

Interleukine-2

"Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."

Trial Locations (1)

33604

CHU de Bordeaux Hôpital Haut Lévêque, Pessac

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT02389231 - Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment | Biotech Hunter | Biotech Hunter